Case Report {#sec1_1}
===========

A 36-year-old woman presented with a 12 × 6 cm ulcer on her right leg (fig. [1](#F1){ref-type="fig"}). She stated that it had been present for 8 years and denied any history of malignancy, ulcerative colitis or rheumatic disease. Biopsy was diagnostic of pyoderma gangrenosum (PG) and prednisone 40 mg daily was initiated. Due to incomplete response, she required several steroid-sparing agents, including dapsone, methotrexate, cyclosporine, mycophenolate, infliximab, adalimumab and azathioprine. Despite this, the ulcers persisted and the prednisone could not be tapered below 20 mg daily. Intravenous immunoglobulin (IVIG) at 2 g/kg monthly was initiated with nearly complete improvement (fig. [2](#F2){ref-type="fig"}). The prednisone was tapered to 5 mg daily and IVIG was tapered to 2 g/kg every 12 weeks. She has since done well on azathioprine and low-dose prednisone and has had no recurrent lesions.

Discussion {#sec1_2}
==========

PG has an annual incidence of 3--10 per million persons, most commonly presents between 20 and 50 years of age and is more common in women. It is characterized by a neutrophilic infiltrate that is believed to be due to dysregulation of neutrophil function and altered innate immune responses. It frequently presents as painful ulcers that often follow surgery or trauma and is commonly misdiagnosed as infectious or ischemic lesions \[[@B1]\].

Initial therapy consists of corticosteroids, although steroid-sparing agents have been used, including dapsone, minocycline, methotrexate, cyclosporine, mycophenolate and TNFα inhibitors. IVIG is typically used after other treatments have failed. Careful wound care and avoidance of debridement and surgery is key \[[@B1]\].

We reviewed 20 cases of IVIG therapy in PG that are described in table [1](#T1){ref-type="table"} and table [2](#T2){ref-type="table"}. Table [1](#T1){ref-type="table"} describes 13 cases that were treated with IVIG 2 g/kg (except for two in whom the dose was 1.5 and 2.5 g/kg, respectively). 12 of these achieved complete or nearly complete remission; 2 had disease recurrence that required repeated courses of IVIG. Both instances of recurrent disease responded to repeat treatment with IVIG. Table [2](#T2){ref-type="table"} describes 7 patients treated with lower-dose IVIG (0.5 g/kg). All had major or complete response, though all required continued corticosteroids, with 4 requiring additional immunosuppressive therapy.

Based on this case and our review of the literature, we believe that IVIG is a useful therapeutic option in refractory PG and can be considered in cases of resistance to or intolerance of standard immunomodulatory therapy.

This work was conducted at the University of Alabama, Birmingham, USA.
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![PG lesion prior to IVIG therapy.](cde-0006-0239-g01){#F1}

![PG lesion post IVIG therapy.](cde-0006-0239-g02){#F2}

###### 

Thirteen cases of IVIG therapy in PG (all IVIG courses were 2 g/kg unless noted otherwise)

  Age, gender, ref.   Notable past medical history            Initial therapy                      Initial IVIG courses                           Initial response   Relapse   Therapy during IVIG treatment   Number of further IVIG courses   Subsequent response   Follow-up
  ------------------- --------------------------------------- ------------------------------------ ---------------------------------------------- ------------------ --------- ------------------------------- -------------------------------- --------------------- ------------------------------------------------
  35, F \[[@B2]\]     insect bite                             PRD, DAP, CBT, TAC, CSA, MPD         2 (2 weeks apart)                              nearly complete    no        PRD, CSA                        none                             N/A                   clear at 8 months
                                                                                                                                                                                                                                                                      
  48, M \[[@B3]\]     adrenal carcinoma, pemphigus vulgaris   PRD, MMF, CSA, DEX, THL              1                                              complete           yes       PRD, MMF                        yes, 1 course                    complete              clear at 5 months
                                                                                                                                                                                                                                                                      
  17, F \[[@B3]\]     none noted                              PRD, MPD, MMF, CSA                   multiple (number and interval not given)       nearly complete    yes       CSA, MMF                        yes                              complete              clear at 15 months
                                                                                                                                                                                                                                                                      
  37, F \[[@B4]\]     none noted                              PRD, CSA                             4 (monthly)                                    complete           no        PRD                             none                             N/A                   clear at 4 months
                                                                                                                                                                                                                                                                      
  55, M \[[@B5]\]     Ph^+^ CML                               PRD, MCN, DAP, AZA, MMF, SSKI, CSA   3 (monthly)                                    complete           no        PRD                             yes, indefinite                  complete              clear at 8 months
                                                                                                                                                                                                                                                                      
  81, M \[[@B6]\]     trauma                                  CSA                                  6 (monthly)                                    significant        no        MPD                             none                             N/A                   clear at 7 months, then died of cardiac arrest
                                                                                                                                                                                                                                                                      
  58, M \[[@B7]\]     prostate carcinoma                      PRD, MCN                             6 (monthly)                                    significant        no        PRD                             none                             N/A                   stable at 12 months
                                                                                                                                                                                                                                                                      
  66, M \[[@B7]\]     CMML                                    BTM, TAC, PRD                        6 (monthly)                                    significant        no        PRD                             none                             none                  stable at 6 months
                                                                                                                                                                                                                                                                      
  83, M \[[@B8]\]     none noted                              CBT, MCN, PRL                        5 (monthly)                                    significant        no        none                            yes, 5 courses (bi-monthly)      complete              stable at 15 months
                                                                                                                                                                                                                                                                      
  61, F \[[@B9]\]     RA, insect bite                         PRD                                  3 (monthly)                                    marked             no        PRD                             no                               N/A                   stable (unknown)
                                                                                                                                                                                                                                                                      
  62, F \[[@B10]\]    none noted                              CSA, GC                              4 (monthly)[^a^](#T1F1){ref-type="table-fn"}   complete           no        PRD                             no                               N/A                   stable at 12 months
                                                                                                                                                                                                                                                                      
  61, M \[[@B11]\]    MDS                                     PRL, MPD                             2 (monthly)                                    marked             no        PRL, PRD                        no                               N/A                   stable at 3 months
                                                                                                                                                                                                                                                                      
  26, F \[[@B12]\]    twin pregnancy                          DAP, MPD                             4 (monthly)[^b^](#T1F2){ref-type="table-fn"}   significant        no        MPD                             no                               N/A                   stable (unknown)

The authors defined all clinical responses -- there is no uniform standard for clinical response in PG.

AZA = Azathioprine; BTM = betamethasone (topical); CBT = clobetasol (topical); CMML = chronic myelomonocytic leukemia; CSA = cyclosporine A; DAP = dapsone; DEX = dexamethasone; GC = glucocorticoid (drug/route not specified); MCN = minocycline; MDS = myelodysplastic syndrome; MMF = mycophenolate mofetil; MPD = methylprednisolone; Ph^+^ CML = Philadelphia chromosome-positive chronic myeloid leukemia; PRD = prednisone; PRL = prednisolone; RA = rheumatoid arthritis; SSKI = potassium iodide; TAC = tacrolimus (topical); THL = thalidomide.

IVIG course 2.5 g/kg.

IVIG course 1.5 g/kg.

###### 

Seven cases of IVIG therapy (0.5 g/kg) in PG (all data are from Kreuter et al. \[[@B13]\])

  Age, gender   Associated disease            Concurrent immunosuppression   Treatment response
  ------------- ----------------------------- ------------------------------ --------------------
  47, F         ankylosing spondylitis        SGC                            complete
  63, F         monoclonal gammopathy (IgA)   SGC, MMF, CSA                  complete
  31, M         ankylosing spondylitis        SGC, AZA, IFX                  complete
  79, F         monoclonal gammopathy (IgA)   SGC                            complete
  40, F         ulcerative colitis            SGC                            major
  49, F         ulcerative colitis            SGC, AZA, CSA                  major
  81, F         ulcerative colitis            SGC, CSA                       complete

The authors defined all clinical responses -- there is no uniform standard for clinical response in PG.

AZA = Azathioprine; CSA = cyclosporine A; IFX = infliximab; MMF = mycophenolate mofetil; SGC = systemic glucocorticoids.
